Peter Malfertheiner - Infectious Diseases

Author Information

Peter Malfertheiner is a distinguished researcher affiliated with the Department of Gastroenterology, Hepatology and Infectious Diseases at Otto-von-Guericke University Hospital in Magdeburg, Germany. His work primarily focuses on gastroenterology and hepatology, with a significant interest in infectious diseases as well. Through his extensive research, he has contributed to advancing understanding and treatment strategies in these fields.

Research Contributions

Peter Malfertheiner has made substantial contributions to the study of gastrointestinal diseases, particularly focusing on conditions such as gastric cancer and Helicobacter pylori infection. His research includes examining the molecular and genetic aspects of these diseases, as evidenced by his work on the expression of long non-coding RNA in gastric cancer. He has also contributed to studies on hepatocellular carcinoma, exploring predictive factors for treatment outcomes. His work often integrates innovative diagnostic approaches, such as the development of new tests for Helicobacter pylori and the use of circulating cell-free DNA for early detection of liver cancer.

Aliases

Peter Malfertheiner is also known by aliases such as P Malfertheiner and P. Malfertheiner. These variations appear in different publications and databases.

Publication and Citation Metrics

Total Citation Count	42,573
H-Index	86
Total Number of Papers	1,433

Publications:

Differential expression of long non-coding RNA HOTAIR in intestinal metaplasia and gastric cancer.

DOI: 10.14309/ctg.0000000000000483

Year: 2022

Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis

DOI: 10.1007/s00432-022-03953-y

Year: 2022

Development and external validation of the Munich Sorafenib Evaluation Score for hepatocellular carcinoma.

DOI: 10.1159/000524336

Year: 2022

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

DOI: 10.1186/s40644-021-00439-x

Year: 2022

[Helicobacter pylori-New aspects of forthcoming guidelines].

DOI: 10.1007/s00108-022-01275-2

Year: 2022

NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial

DOI: 10.3390/cancers13112787

Year: 2021

Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis

DOI: 10.3390/cancers13030521

Year: 2021

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: a Network Meta-Analysis.

DOI: 10.1053/j.gastro.2021.04.012

Year: 2021

[Prevention of gastrointestinal cancer].

DOI: 10.1055/a-1540-7539

Year: 2021

New rapid Helicobacter pylori blood test based on dual detection of FliD and CagA antibodies for on-site testing.

DOI: 10.1016/j.cgh.2021.11.008

Year: 2021

What to Do If Infection is Suspected Post-Transfusion?

What is Fatty Acid Biosynthesis?

What is the Future of Infectious Diseases Training?

What Hygiene Practices Should Be Followed in Healthcare Settings?

Can Surface Contamination Cause Infection?

What Are Some Success Stories of One Health in Action?

How Can Transmission Be Prevented?

What Causes Headaches in Infectious Diseases?

How is the Warburg Effect Related to Infectious Diseases?

How Can We Prevent Culex-Transmitted Diseases?

Partnered Content Networks

Relevant Topics